Analysis of the association between plasma PCSK9 and Lp(a) in Han Chinese

Proprotein convertase subtilisin-kexin type 9 as a biomarker for the severity of coronary artery disease

(2015) Sha Li et al.   ANNALS OF MEDICINE

Role of Insulin in the Regulation of Proprotein Convertase Subtilisin/Kexin Type 9Significance

(2015) Ji Miao et al.   ARTERIOSCLEROSIS THROMBOSIS AND VASCULAR BIOLOGY

Lipoprotein(a) – An independent causal risk factor for cardiovascular disease and current therapeutic options

(2015) Ursula Kassner et al.   ATHEROSCLEROSIS SUPPLEMENTS

‘LDL-C’ = LDL-C + Lp(a)-C

(2015) Calvin Yeang et al.   CURRENT OPINION IN LIPIDOLOGY

Role of lipoprotein(a) in predicting the severity of new on-set coronary artery disease in type 2 diabetics: A Gensini score evaluation

(2015) Juan Chen et al.   Diabetes & Vascular Disease Research

Association Between Familial Hypercholesterolemia and Prevalence of Type 2 Diabetes Mellitus

(2015) Joost Besseling et al.   JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION

Lipoprotein(a) Catabolism Is Regulated by Proprotein Convertase Subtilisin/Kexin Type 9 through the Low Density Lipoprotein Receptor

(2015) Rocco Romagnuolo et al.   JOURNAL OF BIOLOGICAL CHEMISTRY

The apoB-to-PCSK9 ratio: A new index for metabolic risk in humans

(2015) Hanny Wassef et al.   Journal of Clinical Lipidology

Plasma proprotein convertase subtilisin/kexin type 9 is associated with Lp(a) in type 2 diabetic patients

(2015) Ymène Nekaies et al.   JOURNAL OF DIABETES AND ITS COMPLICATIONS

Serum lipoprotein (a) concentrations are inversely associated with T2D, prediabetes, and insulin resistance in a middle-aged and elderly Chinese population

(2015) Lin Ding et al.   JOURNAL OF LIPID RESEARCH

Relation of resistin to proprotein convertase subtilisin–kexin type 9 levels in coronary artery disease patients with different nutritional status

(2015) S. Li et al.   JOURNAL OF ENDOCRINOLOGICAL INVESTIGATION

Association of plasma PCSK9 levels with white blood cell count and its subsets in patients with stable coronary artery disease

(2014) Sha Li et al.   ATHEROSCLEROSIS

PCSK9

(2014) Nabil G. Seidah et al.   CIRCULATION RESEARCH

Lipoprotein(a) metabolism

(2014) Stefania Lamon-Fava et al.   CURRENT OPINION IN LIPIDOLOGY

Circulating PCSK9 levels correlate with the serum LDL cholesterol level in newborn infants

(2014) Shunsuke Araki et al.   EARLY HUMAN DEVELOPMENT

Relation of circulating PCSK9 concentration to fibrinogen in patients with stable coronary artery disease

(2014) Yan Zhang et al.   Journal of Clinical Lipidology

Reduction in Lipoprotein(a) With PCSK9 Monoclonal Antibody Evolocumab (AMG 145)

(2014) Frederick J. Raal et al.   JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY

Diabetic dyslipidemia

(2014) Liya Wu et al.   METABOLISM-CLINICAL AND EXPERIMENTAL

Plasma PCSK9 Levels Are Elevated with Acute Myocardial Infarction in Two Independent Retrospective Angiographic Studies

(2014) Naif A. M. Almontashiri et al.   PLoS One

AMG145, a Monoclonal Antibody Against Proprotein Convertase Subtilisin Kexin Type 9, Significantly Reduces Lipoprotein(a) in Hypercholesterolemic Patients Receiving Statin Therapy

(2013) Nihar R. Desai et al.   CIRCULATION

Death and Dysfunction of Transplanted  -Cells: Lessons Learned From Type 2 Diabetes?

(2013) K. J. Potter et al.   DIABETES

New therapeutic principles in dyslipidaemia: focus on LDL and Lp(a) lowering drugs

(2013) Giuseppe Danilo Norata et al.   EUROPEAN HEART JOURNAL

High levels of lipoprotein(a) are associated with a lower prevalence of diabetes with advancing age: Results of a cross-sectional epidemiological survey in Gran Canaria, Spain

(2012) Mauro Boronat et al.   Cardiovascular Diabetology

Lipoprotein(a) as a Potential Causal Genetic Risk Factor of Cardiovascular Disease

(2012) Sotirios Tsimikas et al.   JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY

Plasma proprotein convertase subtilisin kexin type 9 is not altered in subjects with impaired glucose metabolism and type 2 diabetes mellitus, but its relationship with non-HDL cholesterol and apolipoprotein B may be modified by type 2 diabetes mellitus: The CODAM study

(2011) M.C.G.J. Brouwers et al.   ATHEROSCLEROSIS

Lack of association between plasma PCSK9 and LDL-apoB100 catabolism in patients with uncontrolled type 2 diabetes

(2011) Bruno Vergès et al.   ATHEROSCLEROSIS

Genetic variants, plasma lipoprotein(a) levels, and risk of cardiovascular morbidity and mortality among two prospective cohorts of type 2 diabetes

(2011) Qibin Qi et al.   EUROPEAN HEART JOURNAL

Association between plasma PCSK9 and gamma-glutamyl transferase levels in diabetic patients

(2010) Bertrand Cariou et al.   ATHEROSCLEROSIS

Serum PCSK9 is associated with multiple metabolic factors in a large Han Chinese population

(2010) Qin Cui et al.   ATHEROSCLEROSIS

Plasma PCSK9 is increased by Fenofibrate and Atorvastatin in a non-additive fashion in diabetic patients

(2010) P. Costet et al.   ATHEROSCLEROSIS

Relationship of plasma apolipoprotein M with proprotein convertase subtilisin–kexin type 9 levels in non-diabetic subjects

(2010) Paul J.W.H. Kappelle et al.   ATHEROSCLEROSIS

Lipoprotein(a) and Risk of Type 2 Diabetes

(2010) S. Mora et al.   CLINICAL CHEMISTRY

Lipoprotein(a) as a cardiovascular risk factor: current status

(2010) Børge G. Nordestgaard et al.   EUROPEAN HEART JOURNAL

Plasma PCSK9 Is Associated with Age, Sex, and Multiple Metabolic Markers in a Population-Based Sample of Children and Adolescents

(2009) A. Baass et al.   CLINICAL CHEMISTRY

Genetic and Metabolic Determinants of Plasma PCSK9 Levels

(2009) Susan G. Lakoski et al.   JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM

Plasma PCSK9 Concentrations Correlate with LDL and Total Cholesterol in Diabetic Patients and Are Decreased by Fenofibrate Treatment

(2008) G. Lambert et al.   CLINICAL CHEMISTRY